Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
2023年7月28日 - 5:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
Schedule
14A Information
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed
by the Registrant ☒ |
Filed
by a Party other than the Registrant ☐ |
Check
the appropriate box:
☐ |
Preliminary
Proxy Statement |
|
|
☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive
Proxy Statement |
|
|
☒ |
Definitive
Additional Materials |
|
|
☐ |
Soliciting
Material Pursuant to §240.14a-12 |
Lineage
Cell Therapeutics, Inc.
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
☒ |
No
fee required. |
|
|
☐ |
Fee
paid previously with preliminary materials. |
|
|
☐ |
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Lineage Cell Therapeutics (AMEX:LCTX)
過去 株価チャート
から 4 2024 まで 5 2024
Lineage Cell Therapeutics (AMEX:LCTX)
過去 株価チャート
から 5 2023 まで 5 2024